- Open Access
Role of glial 14-3-3 gamma protein in autoimmune demyelination
Journal of Neuroinflammation volume 12, Article number: 187 (2015)
The family of 14-3-3 proteins plays an important role in the regulation of cell survival and death. Here, we investigate the role of the 14-3-3 gamma (14-3-3 γ) subunit for glial responses in autoimmune demyelination.
Expression of 14-3-3 γ in glial cell culture was investigated by reverse transcription polymerase chain reaction (RT-PCR) and immunocytochemistry. 14-3-3 γ knockout mice were subjected to murine myelin oligodendrocyte-induced experimental autoimmune encephalomyelitis (MOG-EAE), an animal model mimicking inflammatory features and neurodegenerative aspects of multiple sclerosis (MS).
Expression studies in cell culture confined expression of 14-3-3 γ to both, oligodendrocytes (OL) and astrocytes. RT-PCR analysis revealed an increased expression of 14-3-3 γ mRNA in the spinal cord during the late chronic phase of MOG-EAE. At that stage, EAE was more severe in 14-3-3 γ knockout mice as compared to age- and gender-matched controls. Histopathological analyses on day 56 post immunization (p.i.) revealed significantly enhanced myelin damage as well as OL injury and secondary, an increase in axonal injury and gliosis in 14-3-3 γ −/− mice. At the same time, deficiency in 14-3-3 γ protein did not influence the immune response. Further histological studies revealed an increased susceptibility towards apoptosis in 14-3-3 γ-deficient OL in the inflamed spinal cord.
These data argue for a pivotal role of 14-3-3 γ-mediated signalling pathways for OL protection in neuroinflammation.
Oligodendrocyte (OL) damage and astrocyte activation are key features in multiple sclerosis (MS) plaques as well as in inflamed lesions of rodents suffering from experimental autoimmune encephalomyelitis (EAE), an animal model which mimics many histopathological features of MS. To a large extent, inflammatory demyelination is paralleled by loss of OL in the lesions [31–33]. To date, several factors were identified which govern OL susceptibility after an inflammatory attack in the CNS. Such factors comprise neurotrophic cytokines like ciliary neurotrophic factor, leukemia inhibitory factor, or other neurotrophic factors [2, 19, 22]. Besides investigations on glial growth factors, recent studies suggest a role of oligodendroglial death or pro/anti-apoptotic pathways in models of demyelination. Among others, candidates include death pathways involving tumor necrosis factor receptors, Fas-FasL interaction, or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) [6, 7, 28, 29]. Yet, some of these studies reveal divergent roles of some pathways in toxic vs. autoimmune-mediated demyelination or in vitro vs. in vivo approaches. Thus, it is still tempting to investigate the role of further molecules implicated in the degeneration of CNS cells during autoimmune demyelination. Here, the family of 14-3-3 proteins may be of particular interest. In mammals, 14-3-3 proteins comprise seven distinct highly homologous, ubiquitously expressed isoforms (γ, β, ζ, η, σ, and τ), which represent about 1 % of the total soluble brain protein. 14-3-3 subunits are involved in a wide variety of physiological processes, including neuronal development, apoptosis, cell cycle control, and signal transduction . The extraordinary large number of more than 100 binding partners for 14-3-3 proteins suggests a role as major cellular regulator. To date, a plethora of studies describe a role of 14-3-3 proteins in the pathogenesis of chronic as well as acute neurodegenerative disorders, including Creutzfeldt-Jakob disease, Alzheimer’s disease, amyotrophic lateral sclerosis, or stroke . The function of 14-3-3 proteins in these conditions comprises several mechanisms, which may include basic cellular processes like induction, but also the prevention from apoptotic processes depending on the cell type or disease model studied. To assess the role of 14-3-3 proteins in autoimmune demyelination, we employ mice deficient for the 14-3-3 gamma subunit (14-3-3 γ −/− mice). If not challenged, these mice display a normal anatomy and behavior. Upon inoculation with pathogenic prion protein, survival rates in 14-3-3 γ −/− mice are unchanged . However, 14-3-3 γ deficiency may impair the recruitment of activation-induced cytidine deaminase to immunoglobulin H switch regions and is thus involved in class switch DNA recombination, a mechanism that diversifies the biological antibody response .
Here, we investigate the role of 14-3-3 γ protein in glia cell culture and in myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-induced EAE, a model of neuroinflammation with neurodegenerative features. Our data identify a pivotal role of 14-3-3 γ deficiency for OL apoptosis in neuroinflammation.
Materials and methods
Glial cell culture
Cell culture experiments were performed with primary murine oligodendroglial precursor cells (OPC) or primary murine astrocytes which were prepared according to established protocols with some modifications [13, 25, 41]. OPC were obtained via anti-O4 MACS sorting and cultured on poly-D-lysine-coated coverslips in serum-free neuro basal medium with addition of NeuroBrew-21 (Miltenyi, Bergisch-Gladbach, Germany).
14-3-3 γ −/− mice were backcrossed onto a C57BL/6 background for ten times and bred at the in-house animal care facilities at the University of Ulm, Germany. Control C57BL/6 mice for EAE experiments were derived from the same breeding colony. Female mice for animal experimentation were 10–12 weeks old, and body weight was in a range of 20–25 g. Animals were housed in a room with controlled light cycle and were given commercial food pellets and water ad libitum. All animal experiments were approved by the respective state authorities for animal experimentation (LANUV, Recklinghausen, Germany).
Induction and clinical evaluation of EAE
For induction of EAE, mice received a s.c. injection at flanks and tail base of 200 μg MOG 35-55 peptide (Charité, Berlin, Germany) in PBS emulsified in an equal volume of CFA containing Mycobacterium tuberculosis H37RA (Difco, Detroit MI, USA) at a final concentration of 2 mg/ml. Two injections of pertussis toxin (List via Quadratech, UK; 200 ng per mouse post immunization (p.i.)) were given at the time point of immunization and 48 h later. Animals were weighed and scored for clinical signs of disease on a daily basis. Disease severity was assessed using a scale ranging from 0 to 10; scores were as follows : 0 = normal; 1 = reduced tone of tail; 2 = limp tail, impaired righting; 3 = absent righting; 4 = gait ataxia; 5 = mild paraparesis of hind limbs; 6 = moderate paraparesis; 7 = severe paraparesis or paraplegia; 8 = tetraparesis; 9 = moribund; and 10 = death.
In the chronic phase of the disease (day 56 p.i.), mice were anesthetized with ketanest and rompun and then were transcardially perfused with saline followed by 4 % of paraformaldehyde. The complete spinal cord was carefully removed, and 8–10 axial sections were further processed for routine paraffin embedding. Paraffin sections were subjected to Bielschowsky silver impregnation, Luxol fast blue, or Cresyl Violet staining to assess parameters of axonal injury, demyelination, or neuronal damage, respectively.
Immunohistochemistry and immunocytochemistry
Immunohistochemistry was performed with 3 μm paraffin sections as described . If necessary, antigen unmasking was achieved by heat pre-treatment of sections for 30 min in 10 mM citric acid buffer (Mac-3, APP) or 1 mM EDTA (CD3) in a steamer. After inhibition of unspecific binding with 10 % bovine serum albumin (BSA), sections were incubated overnight at 4 °C with the appropriate primary antibody in 1 % BSA. Secondary antibodies were used as indicated below. After blocking of endogenous peroxidase with H2O2, the peroxidase-based ABC detection system (Vector, Schwalbach, Germany) was employed with DAB as the chromogenic substrate. Specificity of staining was confirmed by omitting the primary antibody as a negative control. T cells were labelled by rat anti-CD3 (Serotec; Wiesbaden, Germany; 1:200); macrophages by rat anti-mouse Mac-3 (BD Pharmingen, Heidelberg, Germany 1:200); astrocytes by rabbit anti-mouse glial fibrillary acidic protein (GFAP) (DAKO, Hamburg, Germany 1:1000); and OL with a rabbit anti-NogoA antibody (Santa Cruz, Heidelberg, Germany 1:100) each with appropriate secondary antibodies (1:200, Vector via Linaris, Dossenheim, Germany). Demyelination was assessed with a mouse anti-mouse 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase) antibody (SMI91, Sternberger Monoclonals via Covance, Freiburg, Germany).
Proliferating OPC were stained by double labelling with rabbit anti-Olig2 (Merck Millipore, Schwalbach, Germany; 1:500) and mouse anti-Ki-67 (BD Pharmingen, Heidelberg, Germany; 1:100) with Alexa 488 or Alexa 647 conjugated secondary antibodies, respectively (Invitrogen, Darmstadt, Germany). Apoptotic cells were labelled with a rabbit antibody directed against activated caspase 3 (Cell Signaling via New England Biolabs, Frankfurt, Germany; 1:150).
Glial cell cultures were stained via immunocytochemistry with a rabbit anti 14-3-3 γ antibody (1:200; kind gift from Prof. Alistair Aitken, Edinburgh, Scotland) and a mouse anti-GFAP (1:1000), a rabbit anti-NogoA (1:100), or a mouse anti-Olig2 antibody (1:200), respectively.
Proliferation assay and ELISA
For spleen-cell recall and proliferation assays, single cell suspensions of the spleen from MOG 35-55 immunized 14-3-3 γ −/− mice and wild-type C57BL/6 mice were prepared 10 days after immunization of mice . Cells (3 × 105) were seeded in 96 well microtiter plates (Nunc, Wiesbaden, Germany) in 100 μl medium. Antigen concentrations were 1, 20, or 100 μg/ml for MOG and 1.25 μg/ml for ConA. Triplicate cultures were maintained at 37 °C in a humidified atmosphere with 5 % CO2 for 48 h. Supernatants were harvested after 2 days of culture. IFN-γ, IL-17, or IL-4 concentrations were determined by sandwich ELISA kits from R&D or BD as described. For proliferation assays, cells were harvested following a 16-h pulse with 0.2 μCi/well 3H-dT (tritiated thymidine, Amersham-Buchler, Braunschweig, Germany). Cells were collected on fiberglass filter paper with a 96-well harvester (Amersham/Pharmacia, Freiburg, Germany), and radioactivity was measured with a 96-well Betaplate liquid scintillation counter.
Reverse transcription polymerase chain reaction (RT-PCR) protocol
Total RNA from OPC, astrocytes (from cell culture as described above) or total spinal cord was purified over RNeasy columns (Qiagen, Hilden, Germany). Reverse transcription was performed with 12 μl of purified RNA with Quanti-Tect Reverse Transcription Kit (Qiagen). RT-PCR for 14-3-3 γ was performed with commercially available primers (Applied Biosystems) and beta-actin as internal control. All PCR reactions were performed on a 7500 Real Time PCR System (Applied Biosystems) in quadruplicates; relative quantification was performed according to Livak and Schmittgen .
Quantitative evaluation of histopathological changes was essentially performed as described earlier . Coded sections were counted by blinded observers by means of overlaying a stereological grid onto the sections and counting inflammatory infiltrates per square millimeter white matter . The extent of demyelination was assessed semi-quantitatively (Image J, Open Source) after CNPase staining on an average of four independent levels of spinal cord per mouse. CD3, Mac-3, or Olig2/Ki67 double positive cells as well as NogoA, GFAP, Cresyl Violet, or activated caspase 3 positive profiles were quantified on three representative sections, each one of the cervical, thoracic, and lumbar spinal cord by counting two defined areas with the most intense pathology under a 400-fold magnification. For quantification of axons in demyelinated white matter lesions of spinal cord cross sections, silver impregnated profiles were counted on six visual fields involving the cervical, thoracic, and lumbar spinal cord using a grid of 100 μm diameter . Data are presented as relative axonal densities.
For statistical evaluation of clinical course, data were pooled from different experiments. Analysis was performed using the Mann-Whitney U test t test as appropriate depending on normal distribution of data (Prism Graph Pad, La Jolla, USA). All data are given as mean values ± SEM. p values were considered significant at p < 0.05 and highly significant at p < 0.01.
Expression of 14-3-3 γ in EAE and in glial cells
First, we were interested whether 14-3-3 γ is expressed in EAE. To this end, we compared 14-3-3 γ expression in naïve spinal cord to inflamed spinal cord at different time points of EAE (maximum of disease, day 18 or chronic phase of EAE, day 50 and 78, respectively). RT-PCR analyses of spinal cord revealed an sevenfold increase of 14-3-3 γ expression in the spinal cord during EAE, particularly at later time points (* p < 0.05 at day 78 of EAE; Fig. 1a).
Next, we were interested which cells in the spinal cord may have the capacity for 14-3-3 γ expression. Since the increase in 14-3-3 γ expression was most pronounced at later time points of the disease when inflammation has already significantly declined, we focused our analysis on glial cells. RT-PCR for expression of 14-3-3 γ was performed in purified astrocytes and O4 sorted OPC. Expression analyses revealed the presence of 14-3-3 γ in purified OPC as well as in astrocytes with a significant increase as compared to naïve spinal cord (Fig. 1b). To further confine 14-3-3 γ expression to distinct cell types on the protein level, immunocytochemistry after double labelling for 14-3-3 γ and GFAP or Olig2 was performed in glial cell culture. Laser scanning confocal microscopy revealed expression of 14-3-3 γ in the cytoplasm of single astrocytes and OPC while astrocytic processes and some other glial cells were clearly 14-3-3 γ negative (Fig. 1c, d).
Chronic MOG-EAE in 14-3-3 γ knockout mice is more severe
After having established that 14-3-3 γ protein is regulated in EAE and present in glial cells, we were next interested in its function during demyelination. To this end, we investigated chronic MOG-EAE in 14-3-3 γ knockout mice. Unchallenged, these mice do not display any obvious phenotype and show similar body weights as compared to age-matched controls.
After induction of MOG-EAE, disease incidence, mortality, and onset of disease were not different between 14-3-3 γ knockout mice and controls. At the maximum of disease on day 15 p.i., there were no differences between both groups and all mice suffered from severe gait ataxia. Yet, over the following days (16–20 p.i.), 14-3-3 γ knockout mice exhibited an increasing motor impairment with beginning paraparesis while controls already mildly improved. This difference in motor function lasted until the later chronic disease phase (day 56 p.i.) when 14-3-3 γ knockout mice still displayed mild paraparesis as compared to controls which showed mild improvement and only suffered from mild gait ataxia (Fig. 2 ).
Enhanced tissue damage in 14-3-3 γ-deficient mice suffering from chronic EAE
To unravel the mechanism behind the more severe EAE course in 14-3-3 γ knockout mice after the first maximum of disease, we performed a histopathological analysis of spinal cord cross sections in the chronic disease phase on day 56 p.i. Upon blinded, semiquantitative analysis of demyelination after Luxol fast blue staining, the extent of demyelination was significantly increased in 14-3-3 γ knockout mice by about 40 %. Similar results were obtained after immunohistochemistry for CNPase as another myelin marker (Table 1; Fig. 3a, b). In a next step, we quantified the numbers of activated astrocytes by immunohistochemistry for GFAP. As compared to controls, 14-3-3 γ knockout mice displayed a 30 % increase in GFAP positive reactive astrocytes in the white matter (Fig. 3c, d and Table 1). At the same time, EAE diseased knockout mice showed a 30 % decrease in numbers of NogoA positive OL in the spinal cord (Fig. 3e, f and Table 1). In naïve 14-3-3 γ knockout mice, the numbers of NogoA positive OL in the spinal cord were not different as compared to age- and gender-matched controls (Additional file 1: Figure S1A–C).
Finally, we performed a stereological analysis to quantify axonal densities in demyelinated lesions and densities of alpha motor neurons in the anterior horn. Blinded quantification of axons after silver impregnation revealed a significant 21.5 % decrease of axonal densities in lesions of 14-3-3 γ knockout mice (Fig. 3g, h and Table 1). In contrast, the numbers of neurons in the spinal cord gray matter were not different between knockout mice and controls (Table 1).
In summary, histopathology analysis of chronic EAE reveals enhanced tissue damage in 14-3-3 γ knockout mice with increased demyelination and gliosis, but reduced numbers of OL.
14-3-3 γ deficiency does not alter the immune response in MOG-EAE
To investigate the mechanism behind the increase tissue damage in chronic EAE of 14-3-3 γ knockout mice, we performed an immunological analysis. Blinded quantification of CD3 positive T cells and Mac-3 positive macrophages and microglia on spinal cord cross sections at day 56 p.i. showed no differences in immune cell infiltration between 14-3-3 γ knockout mice and controls (Fig. 4a, b). To investigate effects of 14-3-3 γ deficiency on T cell responses in more detail, we investigated T cell proliferation in lymphocyte primary culture and cytokine production in the spleen cell primary culture after immunization with MOG 35-55. In a set of experiments with MOG 35-55 as recall antigen or polyclonal stimulation with ConA, neither T cell proliferation nor production of the Th1 cytokine interferon gamma, the Th17 cytokine interleukin-17, or the Th2 cytokine interleukin-4 was changed in 14-3-3 γ-deficient cultures as compared to matched wild-type controls (Fig. 4c–f).
In summary, the more severe clinical course and enhanced tissue damage in 14-3-3 γ −/− mice after immunization with MOG 35-55 is not governed by an altered T cell response.
14-3-3 γ deficiency leads to enhanced OL apoptosis after inflammatory challenge
The enhanced oligodendroglial and myelin damage in chronic EAE of 14-3-3 γ knockout mice in the setting of an intact immune response points towards glia intrinsic mechanisms responsible for the increased tissue injury. Since 14-3-3 proteins are known to be involved in the regulation of apoptosis, we investigated the effect of 14-3-3 γ deficiency on OL apoptosis after an inflammatory attack. First, we quantified the overall numbers of apoptotic cells on spinal cord cross sections on day 56 of MOG-EAE by staining for activated caspase 3 (Fig. 5a, b). Upon blinded quantification, 14-3-3 γ-deficient mice displayed a 50 % increase in activated caspase 3 positive cells indicative of apoptosis (Fig. 5c). To further investigate oligodendroglial cells, we additionally quantified the numbers of OL with pyknotic or fragmented nuclei by morphological criteria after staining for NogoA and Hemalaun (Fig. 5d, e). Blinded quantification of the spinal cord cross sections on day 56 of MOG-EAE revealed a 40 % increase of apoptotic OL in 14-3-3 γ-deficient mice (Fig. 5f) indicating that most of the apoptotic cells at this late time of EAE are indeed OL.
In contrast, blinded quantification of Olig2/Ki67 double positive proliferating OPC did not reveal differences between wild-type controls and 14-3-3 knockout mice, neither on day 56 of EAE nor between naïve mice of both genotypes (Additional file 2: Figure S2). In summary, 14-3-3 γ deficiency in autoimmune demyelination is associated with increased apoptosis of oligodendroglial cells but no changes in OPC proliferation.
Our study reveals that 14-3-3 γ protein is present in oligodendroglial cells and that 14-3-3 γ deficiency leads to more severe chronic EAE with enhanced demyelination, OL loss, and increased OL apoptosis. Thus, T cell-mediated neuroinflammation in the setting of 14-3-3 γ deficiency may lead to increased loss of OL which in turn results in increased demyelination, secondary axonal damage, and finally a more severe clinical disease course. These data imply 14-3-3 γ protein as an important factor for OL survival in autoimmune demyelination. Our data on the role of a 14-3-3 subunit in OL extend previous studies on the presence of 14-3-3 proteins in glial cell and particularly astrocytes during development  as well as in models of in vitro cell stress, stroke, and also MS lesions [3, 9, 35, 36]. While 14-3-3 subunits and also 14-3-3 γ has been implicated in survival of neurons in different neurodegenerative diseases , effects on axonal densities in our model may be rather secondary due to enhanced demyelination and OL damage. Although MOG-EAE may affect neurons in the spinal cord [17, 46], neuronal numbers were not significantly different between 14-3-3 γ knockout mice and controls thus further arguing against a primary effect of 14-3-3 γ on neurons and direct neuronal degeneration in EAE.
Thus, our data add 14-3-3 γ to an array of intracellular signalling molecules or pathways which have already been implicated in OL survival and apoptosis during autoimmune demyelination. Among others, these factors comprise PUMA, BAD, Bcl-2, Akt, p53, TNF receptors, TRAIL, or also IAP family members [9, 12, 14, 15, 28, 34, 39, 40, 49]. Yet, for some of these pathways, divergent data on their role in cell culture vs. in vivo models exist, which points to the importance of testing the relevance of such pathways in different disease models of demyelination. This may be also of relevance for a putative role of 14-3-3 γ for repair or remyelination after a demyelinating attack. Since 14-3-3 γ may protect OL from cell death, it may also facilitate OL repopulation and thus repair either via direct effects on OPC or indirectly via preservation of oligodendroglial cells in or around demyelinating lesions. Yet, repair and remyelination is very incomplete in murine MOG-EAE in C57BL/6 mice  and a proper evaluation of these questions need further studies in other, e.g., toxic models of demyelination with better remyelination .
The detection of 14-3-3 γ protein not only in OL but also in astrocytes may additionally suggest role of 14-3-3 γ in astrocyte depletion thus indirectly influencing the extent of demyelination as recently discussed in different models after astrocyte ablation [38, 45, 47].
The concept of a protective role of 14-3-3 proteins in oligodendroglial cells may also have consequences for the assessment of 14-3-3 in CSF as biomarker. Here, an increase of 14-3-3 as a bulk maker for neuronal degeneration has been described in several neurodegenerative diseases and also MS [5, 26, 27, 30, 42, 48]. Yet, lacking sufficient reproducibility, the value of 14-3-3 in the CSF as prognostic biomarker in MS remains ambiguous so far . Our data indicate that at least 14-3-3 γ may rather indicate primary damage of oligodendroglia and myelin than injury to neurons or axons in autoimmune demyelination. Thus, further human studies on correlation of CSF 14-3-3 with clinical or magnetic resonance imaging surrogates of myelin damage, e.g., using magnetization transfer ratio or diffusion tensor imaging may be helpful .
Finally, our data do not argue for a pivotal role of 14-3-3 γ in immune cells during MOG-EAE, although 14-3-3 adaptor protein-dependent functions have been described in some immune cell-types. In Toll-like receptors pathways of the innate immune response, rather 14-3-3 ε and σ subunits than 14-3-3 γ proteins seem to play a role . In lymphocytes, a role for 14-3-3 proteins has mainly been described in cells of the B cell lineage. Here, the 14-3-3 γ and σ subunits were recently shown to play a role in B cell homeostasis and class switch recombination [44, 50]. However, MOG 35-55 EAE in C57BL/6 mice is a mainly T cell-mediated model of autoimmunity where B cells do not play a vital role for mechanisms of tissue damage . In this study, 14-3-3 γ deficiency did not impact on T cell function including T cell proliferation, cytokine production, and T cell infiltration. Thus, 14-3-3 γ-related immune effects on the neuroinflammation may not be immediately expected based on all available data.
In summary, we here identify 14-3-3 γ protein as a protective factor for OL in autoimmune demyelination. The characterization of such factors may further improve our understanding on mechanisms of tissue destruction in MS and may eventually contribute to new innovative therapeutic approaches in MS aiming at direct protection of glial cells and myelin or even tissue repair. In this context, future studies in other models of demyelination or with potent small molecule modulators of 14-3-3 pathways are highly warranted.
central nervous system
counts per minute
experimental autoimmune encephalomyelitis
Luxol fast blue
myelin oligodendrocyte glycoprotein
oligodendrocyte precursor cell
Butt AQ, Ahmed S, Maratha A, Miggin SM. 14-3-3epsilon and 14-3-3sigma inhibit Toll-like receptor (TLR)-mediated proinflammatory cytokine induction. J Biol Chem. 2012;287(46):38665–79.
Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med. 2002;8(6):613–9.
Chen XQ, Fung YW, Yu AC. Association of 14-3-3gamma and phosphorylated bad attenuates injury in ischemic astrocytes. J Cereb Blood Flow Metab. 2005;25(3):338–47.
Chen XQ, Liu S, Qin LY, Wang CR, Fung YW, Yu AC. Selective regulation of 14-3-3eta in primary culture of cerebral cortical neurons and astrocytes during development. J Neurosci Res. 2005;79(1–2):114–8.
Colucci M, Roccatagliata L, Capello E, Narciso E, Latronico N, Tabaton M, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler. 2004;10(5):477–81.
D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci. 1995;15(11):7293–300.
D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med. 1996;184(6):2361–70.
Dittel BN, Urbania TH, Janeway Jr CA. Relapsing and remitting experimental autoimmune encephalomyelitis in B cell deficient mice. J Autoimmun. 2000;14(4):311–8.
Dong H, Fazzaro A, Xiang C, Korsmeyer SJ, Jacquin MF, McDonald JW. Enhanced oligodendrocyte survival after spinal cord injury in Bax-deficient mice and mice with delayed Wallerian degeneration. J Neurosci. 2003;23(25):8682–91.
Gajofatto A, Bongianni M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci. 2011;12(11):7960–70.
Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, Pike GB, et al. Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol. 2009;66(3):375–81.
Hagemeier K, Lurbke A, Hucke S, Albrecht S, Preisner A, Klassen E, et al. Puma, but not noxa is essential for oligodendroglial cell death. Glia. 2013;61(10):1712–23.
Herrero-Herranz E, Pardo LA, Bunt G, Gold R, Stuhmer W, Linker RA. Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation. Am J Pathol. 2007;171(2):589–98.
Kuhlmann T, Lucchinetti C, Zettl UK, Bitsch A, Lassmann H, Bruck W. Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia. 1999;28(1):34–9.
Ladiwala U, Li H, Antel JP, Nalbantoglu J. p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. J Neurochem. 1999;73(2):605–11.
Lee DH, Geyer E, Flach AC, Jung K, Gold R, Flugel A, et al. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 2012;123(2):247–58.
Lee DH, Kubera K, Rosenthal B, Kaltschmidt B, Kaltschmidt C, Gold R, et al. Neuronal NF-kappaB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination. J Neuroimmunol. 2012;246(1–2):38–42.
Lindner M, Heine S, Haastert K, Garde N, Fokuhl J, Linsmeier F, et al. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol Appl Neurobiol. 2008;34(1):105–14.
Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol. 2009;29(1):43–68.
Linker RA, Kruse N, Israel S, Wei T, Seubert S, Hombach A, et al. Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J Immunol. 2008;180(4):2204–13.
Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 2010;133(Pt 8):2248–63.
Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med. 2002;8(6):620–4.
Linker RA, Rott E, Hofstetter HH, Hanke T, Toyka KV, Gold R. EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol Dis. 2005;19(1–2):218–28.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
Magnus T, Chan A, Linker RA, Toyka KV, Gold R. Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol. 2002;61(9):760–6.
Martinez-Yelamos A, Rovira A, Sanchez-Valle R, Martinez-Yelamos S, Tintore M, Blanco Y, et al. CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol. 2004;251(10):1278–9.
Martinez-Yelamos A, Saiz A, Sanchez-Valle R, Casado V, Ramon JM, Graus F, et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology. 2001;57(4):722–4.
Matysiak M, Jurewicz A, Jaskolski D, Selmaj K. TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain. 2002;125(Pt 11):2469–80.
Mc GC, Volckaert T, Wolke U, Sze M, de Rycke R, Waisman A, et al. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination. J Immunol. 2010;185(12):7646–53.
Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002;58(2):192–7.
Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 1994;117(Pt 6):1311–22.
Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis. Pathology of recurrent lesions. Brain. 1993;116(Pt 3):681–93.
Raine CS. The Norton lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol. 1997;77(2):135–52.
Rena HA, Hagemeier K, Lurbke A, Held J, Friedman H, Peterson A, et al. XIAP protects oligodendrocytes against cell death in vitro but has no functional role in toxic demyelination. Glia. 2012;60(2):271–80.
Satoh J, Tabunoki H, Nanri Y, Arima K, Yamamura T. Human astrocytes express 14-3-3 sigma in response to oxidative and DNA-damaging stresses. Neurosci Res. 2006;56(1):61–72.
Satoh J, Yamamura T, Arima K. The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. Am J Pathol. 2004;165(2):577–92.
Shimada T, Fournier AE, Yamagata K. Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int. 2013;2013:564534.
Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, et al. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain. 2013;136(1):147–67.
Soane L, Cho HJ, Niculescu F, Rus H, Shin ML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. 2001;167(4):2305–11.
Soane L, Rus H, Niculescu F, Shin ML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol. 1999;163(11):6132–8.
Sontheimer H, Trotter J, Schachner M, Kettenmann H. Channel expression correlates with differentiation stage during the development of oligodendrocytes from their precursor cells in culture. Neuron. 1989;2(2):1135–45.
Steinacker P, Aitken A, Otto M. 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol. 2011;22(7):696–704.
Steinacker P, Schwarz P, Reim K, Brechlin P, Jahn O, Kratzin H, et al. Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol. 2005;25(4):1339–46.
Su YW, Hao Z, Hirao A, Yamamoto K, Lin WJ, Young A, et al. 14-3-3sigma regulates B-cell homeostasis through stabilization of FOXO1. Proc Natl Acad Sci U S A. 2011;108(4):1555–60.
Toft-Hansen H, Füchtbauer L, Owens T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia. 2011;59(1):166–76. doi:10.1002/glia.21088.
Vogt J, Paul F, Aktas O, Muller-Wielsch K, Dorr J, Dorr S, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 2009;66(3):310–22.
Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci. 2009;29(37):11511–22.
Wiltfang J, Otto M, Baxter HC, Bodemer M, Steinacker P, Bahn E, et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem. 1999;73(6):2485–90.
Wosik K, Antel J, Kuhlmann T, Bruck W, Massie B, Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem. 2003;85(3):635–44.
Xu Z, Fulop Z, Wu G, Pone EJ, Zhang J, Mai T, et al. 14-3-3 adaptor proteins recruit AID to 5′-AGCT-3′-rich switch regions for class switch recombination. Nat Struct Mol Biol. 2010;17(9):1124–35.
We wish to thank Stephen Meier, Ulm, Germany, for the help with the mouse breeding and Prof. Alasdair Aitken, Division of Biomedical and Clinical Laboratory Sciences, University of Edinburgh, Scotland, for the generous gift of the 14-3-3 γ antibody for immunocytochemistry.
The authors declare that they have no competing interests.
D-HL and RAL took the lead in drafting the manuscript and has made substantial contributions to study concept and design, acquisition of data, and statistical analysis. PS, SS, TT, AMe, and AMa are involved in the acquisition of data and revising it critically for important content. MO revised the manuscript critically and contributed to the study concept and design of the acquisition of data. All authors read and approved the final manuscript.
14-3-3 γ deficiency does not influence numbers of NogoA positive OL in naive mice. A, B Representative sections of the spinal cord lesions from naive mice. Bar represents 200 μm for both sections. Labelling for NogoA positive OL does not reveal any difference between 14-3-3 γ knockout mice and controls (see arrows). C Blinded quantification of NogoA positive OL on the spinal cord cross sections reveals no difference between both groups (n = 3 mice per group, p = n.s.).
14-3-3 γ deficiency does not influence numbers of proliferating OPC on day 56 of MOG-EAE. Blinded quantification of Olig2/Ki67 positive proliferating OPC on spinal cord cross sections does not reveal any difference between both groups (n = 6 vs. eight mice per group, p = 0.35).
About this article
Cite this article
Lee, D., Steinacker, P., Seubert, S. et al. Role of glial 14-3-3 gamma protein in autoimmune demyelination. J Neuroinflammation 12, 187 (2015). https://doi.org/10.1186/s12974-015-0381-x
- Multiple sclerosis
- Knockout mouse